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ABSTRACT 
Objective: The prevalence of diabetes mellitus and obesity was increased world-wide as well as in Iraq. Inflammation plays important role in 
pathogenesis of obesity and type 2 DM. The aim of this study was to investigate the serum levels of the inflammatory markers, insulin resistance, 
and BMI and lipid profile in obese type 2 diabetic Iraqi patients treated with metformin and glibenclamide. 
Methods: This cross sectional study was conducted at Baquba Teaching Hospital, Diyala, Iraq; from January - April 2014. Fasting blood of glucose 
and insuline levels, lipid profile (S. cholesterole,S. triglyceride, and S. HDL),S. Interleukin 6 (IL-6) and C-reactive protein were determined in 30 
subjects; 15 healthy control and 15 diabetic obese patients. 
Results: There was statistically significant difference in BMI, fasting blood sugar, insulin resistance and lipid profile between obese diabetic and 
control group; inflammatory markers were also significantly elevated in diabetic obese patients compared to healthy control.  
Conclusion: There is augmented inflammatory response in Iraqi diabetic obese patients which plays role in higher insulin resistance in these 
patients. Levels of inflammatory markers are increased and related to BMI and dyslipidemia in these patients.  
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INTRODUCTION 
The prevalence of diabetes mellitus (DM) world-wide was estimated 
to be 171 million people in the year 2000 and this is projected to 
increase to 366 million by the year 2030 (1), the prevalence of 
diabetes mellitus and obesity was increased world-wide as well as in 
Iraq. Inflammation plays important role in pathogenesis of the 
disease and inflammatory markers including interleukins and C- 
reactive protein (CRP), are found to be increased in type 2 DM 
(T2DM) patients (2).  
Adipocytes secrete inflammatory cytokine; in addition they develop 
macrophage infiltration (adiposities) which is the source of most of the 
IL-6 in adipose tissue along with other inflammatory markers (3). Not 
only obesity but hyperinsulinism per se, seen in metabolic syndrome and 
type 2 DM, can induce rise in inflammatory markers including IL-6, and 
CRP. High levels of IL-6 have been reported to be associated with insulin 
resistance in adipocytes, hepatocytes and myocytes (4).  
Raised serum IL-6 level in type 2 diabetic patients was found to be 
associated with increased BMI, fasting insulin levels and insulin 
resistance (5). In a prospective study in American females, the 
baseline CRP and IL-6 levels were significantly higher in those who 
later developed T2DM (6) Few studies have been done in Iraqi 
T2DM patients for CRP. No study so far has been done on serum 
levels of IL-6 level in T2DM patients. The present study was done to 
evaluate the serum levels of the inflammatory markers, insulin 
resistance and BMI and lipid profile in obese type 2 diabetic Iraqi 
patients treated with metformin and glibenclamide. 
MATERIALS AND METHODS 
This cross sectional study was conducted at Baquba Teaching 
Hospital, Iraq, from January 2014- April 2014. Approval from ethical 
committee of Ministry of Health, Iraq, was obtained before 
undertaking the research project. 15 healthy control male subjects 
and 15 diabetic male patients who were already on oral 
hypoglycemic agents (metformin and glibenclamide); age being 
54.33± 2.52 year for control group and 55.67± 4.13 year or diabetic 
patients were included in the study as in table 1.  
The diabetic group (n = 15) were diagnosed cases of type 2 diabetes 
mellitus of maximum duration of 5 years. The control group (n = 15) 
comprised of normal healthy individuals. The subjects were selected in 
accordance with inclusion and exclusion criteria. The inclusion criteria 
comprised of T2DM patients diagnosed according to 2013 WHO 
Diabetes criteria. Smokers, type 1 diabetic patients, patients on insulin 
therapy, patients with diabetic complications and patients with acute or 
chronic inflammatory disease were excluded from the study.  
All study patients had proper history; physical examination. All sub-
jects were informed about the nature, significance, implications and 
consequences of the study. They were appraised regarding 
investigational procedures. They were advised not to do any 
exercise or take any non-steroidal anti inflammatory drugs (NSAIDs) 
for two weeks prior to the blood sampling. The written informed 
consent was obtained, and personal particulars informed consent 
was obtained and personal particulars of each subject were noted 
and each was evaluated on the basis of detailed medical history, 
physical examination and laboratory tests. 10 ml of venous blood 
sample was drawn from antecubital vein under aseptic conditions in 
a disposable syringe from each individual. Blood was allowed to clot 
for 30 minutes at room temperature. After retraction of the clot, 
serum was separated by centrifugation at 3000 cycles per second for 
15 minutes. Serum was then transferred to small sterile tubes and 
stored at - 20 °C prior to biochemical analysis. Blood C- reactive 
protein was performed on sysmex automated analyzer, Total 
cholesterol (TC), and triglycerides (TGs) by calorimetric method, 
and high density lipoprotein (HDL); calculated by Freidewald 
formula. IL-6 were determined by Enzyme Amplified Sensitivity 
Immunoassay (EASIA). Insulin resistance was calculated by 
Homeostatic Model of Assessment of insulin resistance (HOMA-IR). 
Statistical analysis was done utilizing program package of SPSS-17. 
IL-6 assay  
Quantitative measurement of IL-6 was done by use of a commercial 
EASIA kit; ‘Bioscience Human IL-6 EASIA kit’ (Catalogue no 
KAC1751, BioSource Europe S. A. Rue de I’Industrie 8 B-1400 
Nivelles Belgium).  
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The assay is a solid phase Enzyme Amplified Sensitivity 
Immunoassay performed on microtiter plate. The minimum 
detectable concentration was estimated to be 2 pg/ml. The intra-
assay and inter-assay coefficient of variation for IL-6 were 5.6% and 
7.5% respectively. 
RESULTS 
Table 1 showed that there is non-significant difference between the 
ages of obese diabetic patients compared to that of healthy subjects, 
while there is a highly significant difference between the two groups 
concerning the BMI. The fasting blood glucose and fasting insulin 
levels in addition to insulin resistance were differ significantly in 
diabetic obese patients compared to healthy subjects table 1. 
 
Table 1: Baseline data of healthy subjects and diabetes obese 
patients 
Variables Healthy subjects 
(n=15) 
Diabetic obese patients 
(n=15) 
Age (year) 54.33±2.52 57.65±4.138 
BMI (kg/m2 21.17±1.62 ) 39.59±2.55* 
F. B. S 
(mmole/l)  
5.95±0.67 12.89±2.1* 
F. S. Insulin 
mIU/L  
9.34±0.93 7.02±0.71* 
HOMA-IR 2.46±0.33 4.04±0.79* 
Results represents mean±SD; *=significant difference P≤0.05 ; 
BMI=body mass index; FBS=fasting blood glucose; HOMA-IR= 
Homeostatic Model of Assessment of insulin resistance. 
 
While the values of total serum cholesterol and serum triglycerides 
were significantly higher in diabetic obese patients compared to 
healthy control, the value of high density lipoprotein was 
significantly lower in diabetic obese patients compared to healthy 
control, table 2.  
The results of inflammatory markers studied were shown in table 3, 
IL-6 and C-reactive protein as; the serum levels of both in-
flammatory markers were significantly higher in diabetic obese 
patients compared to healthy controls.  
 
Table 2: Lipid profile of healthy subjects and diabetes obese 
patients 
Variables Healthy subjects 
(n=15) 








S. HDL (mg/dl) 47±4.72 40±3.81* 
Results represents mean±SD; *=significant difference P≤0.05 ; S. 
HDL=serum high density lipoprotein. 
 
Table 3: Inflammatory markers of healthy subjects and diabetes 
obese patients 
Variables Healthy subjects 
(n=15) 








Results represents mean±SD; *=significant difference (P≤0.05); IL -
6=interleulin-6; CRP=C-reactive protein. 
 
DISCUSSION 
Obesity is associated with a chronic inflammatory response, 
characterized by abnormal adipokine production, and the activation 
of some pro-inflammatory signaling pathways, resulting in the 
induction of several biological markers of inflammation (7). The key 
finding of this study is the close and significant relationship between 
levels of fasting glucose and CRP, Interleukin -6, and insulin 
resistance and changes in lipid profile. These findings in fact indicate 
that higher levels of these parameters in obese individuals lead to 
increased blood glucose. In support of these findings, some clinical 
studies support a close relationship and the role of CRP and other 
inflammatory markers such as IL-6, in hyperglycemia phenomenon 
in relationship with abnormal lipid profile (8, 9). Preliminary human 
studies demonstrated that central obesity is a risk factor for 
decrease in insulin sensitivity, although the molecular mechanisms 
for this are less understood (10). Obesity has been associated with 
elevated levels of CRP as an inflammation marker and elevated in 
serum cholesterol and triglyceride and predictor of cardiovascular 
risk (11). Recent epidemiologic studies have demonstrated 
associations of elevated serum levels of C-reactive protein with 
obesity, visceral adiposity, and insulin resistance, suggesting that a 
chronic inflammatory state is associated with hyperglycemia and 
diabetes through obesity or increased insulin resistance (12, 13, 14). 
The rise in the inflammatory cytokines is the essential step in 
glucotoxicity and lipotoxicity induced mitochondrial injury, 
oxidative stress and beta cell apoptosis in type 2 DM (15).  
Our study found higher levels of, C-reactive protein,and IL-6 in 
diabetic obese patients compared to healthy controls that agreed 
with other studies (16, 17) indicating the role of inflammation in 
pathogenesis of the disease; administration of oral hypoglycemic 
agents in current use such as Metformin and Glibeneclamide to 
diabetic obese patients were unable to correct the glycemic control 
or changes in lipid profile beside increased level of inflammatory 
markers; targeting of these changes may represents an important 
strategy in the treatment of diabetic obese patients that may 
improve the overall situation of such patients. 
In conclusion, there is augmented inflammatory response in Iraqi 
diabetic obese patients which plays role in higher insulin resistance 
in these patients. Levels of inflammatory markers are increased and 
related to BMI and dyslipidemia in these patients. This is the first 
study reporting the association of inflammatory cytokines with 
dyslipidemia and poor glycemic control in diabetic obese Iraqi 
patients.  
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